Yaw Nyame(@yawnyame) 's Twitter Profileg
Yaw Nyame

@yawnyame

Asst Professor @uwurology @SeattleCCA. @OU_Football Fan. Maven wannabe. Opinions my own. L ≠ E.

ID:73898759

linkhttps://www.washington.edu/urology/people/yaw-nyame-md/ calendar_today13-09-2009 14:55:32

1,6K Tweets

1,5K Followers

1,3K Following

SMSNA(@SMSNA_ORG) 's Twitter Profile Photo

Congratulations to our April SMSNA Member of the Month, Marah C. Hehemann, MD! Learn more about Dr. Hehemann on our website: smsna.org/membership/mem…

Congratulations to our April SMSNA Member of the Month, @MarahHehemannMD! Learn more about Dr. Hehemann on our website: smsna.org/membership/mem…
account_circle
Adam B. Weiner, MD(@Adam_Weiner535) 's Twitter Profile Photo

☝️📢Black men in the US have an increased of death from

Prostate Cancer Foundation has realeased screening guidelines specifically for this group of patients 👏

✴️Screening benefits > risks
✴️Age to start screening: 40-45
✴️Start at 40 if greater risk w/ family hx or genetics…

☝️📢Black men in the US have an increased of death from #prostatecancer @PCFnews has realeased screening guidelines specifically for this group of patients 👏 ✴️Screening benefits > risks ✴️Age to start screening: 40-45 ✴️Start at 40 if greater risk w/ family hx or genetics…
account_circle
Prostate Cancer Foundation(@PCFnews) 's Twitter Profile Photo

New evidence-based PCF Prostate Cancer Screening Guidelines for Black Men in the U.S. recommend that Black men consider PSA screening between ages 40-45, and screen annually depending on PSA levels and health status. 🧵⬇️

New evidence-based PCF Prostate Cancer Screening Guidelines for Black Men in the U.S. recommend that Black men consider PSA screening between ages 40-45, and screen annually depending on PSA levels and health status. 🧵⬇️
account_circle
Jeff Tosoian, MD, MPH(@UroOncJT) 's Twitter Profile Photo

Huge thank you to all involved.

Looking for an easier-to-read summary?

Here’s a quick thread on this new (PCa) test, with some context for lay folks… 🧵

account_circle
Adam B. Weiner, MD(@Adam_Weiner535) 's Twitter Profile Photo

🚨New Urine Test for High-Grade 🚨

MyProstateScore 2.0 (MPS2 and MPS2+)

At 95% sensitivity for GG2:
✨ Can📉 unnecessary biopsies by 35-42%

Negative predictive value:
✨≥GG2 - 95-99%
✨≥GG3 - 99%

👏 Jeff Tosoian, MD, MPH

▶️JAMA Oncology link: tinyurl.com/25yzhfdd…

🚨New Urine Test for High-Grade #prostatecancer🚨 MyProstateScore 2.0 (MPS2 and MPS2+) At 95% sensitivity for GG2: ✨ Can📉 unnecessary biopsies by 35-42% Negative predictive value: ✨≥GG2 - 95-99% ✨≥GG3 - 99% 👏 @UroOncJT ▶️@JAMAOnc link: tinyurl.com/25yzhfdd…
account_circle
Toni Choueiri, MD(@DrChoueiri) 's Twitter Profile Photo

1/ The long-awaited OS results from -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in .

nejm.org/doi/full/10.10…

1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…
account_circle
Lee Lab(@jklee_lab) 's Twitter Profile Photo

The Agency has given us the 'study may proceed' for our first-in-human STEAP1 CAR T trial for mCRPC tinyurl.com/u6fc59tx led by Jessica Hawley MD MS Fred Hutchinson Cancer Center! Truly a collaborative effort to tackle prostate cancer! PCF Science CDMRP Institute for Prostate Cancer Research NCI Treatment

account_circle
Scott Lundy MD PhD HCLD(@ScottLundyMDPhD) 's Twitter Profile Photo

This week we bid a fond farewell our Cleveland Clinic Urology research fellow Shin Kuroda 黒田晋之介 as he returns to Yokohama and his busy andrology practice. shin you’re a legend and we will miss your smile and your science dearly. あなたと 働く(はたらく) ことが できて 光栄(こうえい)です

This week we bid a fond farewell our @CleClinicUro research fellow @shinkuro1014 as he returns to Yokohama and his busy andrology practice. shin you’re a legend and we will miss your smile and your science dearly. あなたと 働く(はたらく) ことが できて 光栄(こうえい)です
account_circle
Fred Hutch/UW/SC OCOE(@End_Disparities) 's Twitter Profile Photo

Registration is open for the 2024 Pathways to Equity Symposium on June 6th! Register, learn more, and view the agenda here: bit.ly/pathwaystoequi…

Registration is open for the 2024 Pathways to Equity Symposium on June 6th! Register, learn more, and view the agenda here: bit.ly/pathwaystoequi…
account_circle
Prostate Cancer Foundation(@PCFnews) 's Twitter Profile Photo

This virtual research community is free to join and is for all community members interested in advancing prostate cancer equity research.

If you or someone you know is a Black Prostate Cancer survivor you can register here: bacpacnetwork.org/join

Thank you BACPAC

This virtual research community is free to join and is for all community members interested in advancing prostate cancer equity research. If you or someone you know is a Black Prostate Cancer survivor you can register here: bacpacnetwork.org/join Thank you @BACPACNetwork
account_circle
Marah C. Hehemann, MD(@MarahHehemannMD) 's Twitter Profile Photo

The news I needed to hear today - the VA is expanding IVF coverage for our nations veterans! 🇺🇸 news.va.gov/press-room/va-…

account_circle
Kemi Doll, MD MS(@KemiDoll) 's Twitter Profile Photo

🚨 JOB ALERT 🚨
We are hiring a Staff Research Scientist position.

This is a great opportunity for an MPH/PhD grad with leadership desires...who is looking for a staff position with no faculty trappings.

It's not for everyone, but it might be for you!
uwhires.admin.washington.edu/ENG/candidates…

account_circle
Tom Powles(@tompowles1) 's Twitter Profile Photo

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’
account_circle